(Q52073784)

21 April 2018

title

Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy. (English)

1 reference

21 April 2018

1 reference

1 reference

B E Gidal

1

1 reference

21 April 2018

G D Anderson

2

1 reference

21 April 2018

P R Rutecki

3

1 reference

21 April 2018

R Shaw

4

1 reference

21 April 2018

A Lanning

5

1 reference

21 April 2018

publication date

1 November 2000

1 reference

21 April 2018

published in

Epilepsy Research

1 reference

21 April 2018

volume

42

1 reference

21 April 2018

issue

1

1 reference

21 April 2018

page(s)

23-31

1 reference

21 April 2018

The influence of dosage, age, and comedication on steady state plasma lamotrigine concentrations in epileptic children: a prospective study with preliminary assessment of correlations with clinical response

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900160-1

7 January 2021

Lamotrigine Plasma Concentrations in Children and Adults

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900160-1

7 January 2021

A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900160-1

7 January 2021

Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900160-1

7 January 2021

Pharmacokinetics of lamotrigine in children in the absence of other antiepileptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900160-1

7 January 2021

Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900160-1

7 January 2021

Lamotrigine as add-on drug in children and adolescents with refractory epilepsy and mental delay: an open trial

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900160-1

7 January 2021

Use of lamotrigine in Lennox-Gastaut and related epilepsy syndromes.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900160-1

7 January 2021

Adding lamotrigine to valproate: incidence of rash and other adverse effects. Postmarketing Antiepileptic Drug Survey (PADS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900160-1

7 January 2021

Therapeutic interaction of lamotrigine and sodium valproate in intractable myoclonic epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900160-1

7 January 2021

Lamotrigine-associated rash: risk/benefit considerations in adults and children

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900160-1

7 January 2021

Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900160-1

7 January 2021

Lamotrigine: single-dose pharmacokinetics and initial 1 week experience in refractory epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900160-1

7 January 2021

Valproic acid pharmacokinetics in children: III. Very high dosage requirements

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900160-1

7 January 2021

Optimized high-performance liquid chromatographic method for determination of lamotrigine in serum with concomitant determination of phenytoin, carbamazepine, and carbamazepine epoxide

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900160-1

7 January 2021

Building population pharmacokineticpharmacodynamic models. I. Models for covariate effects

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900160-1

7 January 2021

The role of the old and the new antiepileptic drugs in special populations: mental and multiple handicaps

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900160-1

7 January 2021

Serum concentrations of lamotrigine in epileptic patients: the influence of dose and comedication.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900160-1

7 January 2021

Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900160-1

7 January 2021

A decade of modern epilepsy therapy in institutionalized mentally retarded patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900160-1

7 January 2021

The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900160-1

7 January 2021

Estimation of population characteristics of pharmacokinetic parameters from routine clinical data

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900160-1

7 January 2021

Intractable epilepsy in a population-based series of mentally retarded children

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900160-1

7 January 2021

Meeting the challenge of epilepsy in persons with multiple handicaps

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900160-1

7 January 2021

Intractable epilepsy in children. The efficacy of lamotrigine treatment, including non-seizure-related benefits.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900160-1

7 January 2021

Influence of concurrent antiepileptic medication on the pharmacokinetics of lamotrigine as add-on therapy in epileptic children

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900160-1

7 January 2021

Population pharmacokinetics. Theory and clinical application

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900160-1

7 January 2021

Sodium valproate acutely inhibits lamotrigine metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900160-1

7 January 2021

10.1016/S0920-1211(00)00160-1

Identifiers

DOI

1 reference

21 April 2018

1 reference

21 April 2018